Skip to content
value.today

Repro Med Systems

KRMD
$140 Mmarket cap on Oct 29, 2026+36.9% since Jan 2024
Compare
World rank
#17,538
Revenue
$41 M
For year ending December-2025
Net income
$-3 M
-6.4% margin
SEC filing
Employees
—

Repro Med Systems in brief

Repro Med Systems is a listed company in the Medical Instruments industry, based in Mahwah, New Jersey, USA. Its market value was $140 M on 29 October 2026, which makes it the 17,538th largest listed company in the world and the 3,340th largest in the USA on this site. In the year to December 2025 it had sales of $41 M and a net loss of $3 M. Linda M. Tharby is its chief executive. By market, the largest shares of its 2025 sales came from USA (74%). Its shares trade under the symbol KRMD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Repro Med Systems timeline

3 events, 1996–2025
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. ✎
    Renamed KORU Medical Systems, Inc.
    Formerly Repro Med Systems Inc.
  5. 2025
  6. 💰
    Record revenue of $41 million
    FY2025, the highest of the 8 years on record.

Events of Repro Med Systems from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$72 M$143 M$215 M$286 M2020202120222023202420252026

World rank over time

▼ down 2,790 places since 2020
2020-01-01: #14779#14,77920202021-01-01: #14247#14,24720212022-01-07: #21374#21,37420222022-12-25: #19395#19,39520222023-07-30: #20570#20,57020232024-01-05: #21326#21,32620242026-03-08: #8909#8,90920262026-08-01: #16101#16,10120262026-09-18: #17613#17,61320262026-10-29: #17569#17,5692026

Rank in USA: #3,053 (Jan 2020) · #3,050 (Jan 2021) · #4,185 (Jan 2022) · #3,916 (Dec 2022) · #4,026 (Jul 2023) · #3,682 (Jan 2024) · #1,683 (Mar 2026) · #3,219 (Aug 2026) · #3,317 (Sep 2026) · #3,344 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
3.0×
Price / book
8.2×
Free cash flow yield
-0.3%
Net margin (TTM)
-1.8%
Operating margin
-7.2%
Return on equity
-4.8%
Liabilities / assets
39.5%
Net debt
$-2M
Revenue growth
+22.2%
R&D / revenue
10.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $17M, net income $1M$17MFY18Fiscal year ending Dec 2019: revenue $23M, net income $1M$23MFY19Fiscal year ending Dec 2020: revenue $24M, net income $-1M$24MFY20Fiscal year ending Dec 2021: revenue $23M, net income $-5M$23MFY21Fiscal year ending Dec 2022: revenue $28M, net income $-9M$28MFY22Fiscal year ending Dec 2023: revenue $29M, net income $-14M$29MFY23Fiscal year ending Dec 2024: revenue $34M, net income $-6M$34MFY24Fiscal year ending Dec 2025: revenue $41M, net income $-3M$41MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$41M+22.2%$-3M$-3M-6.4%
Dec 2024$34M+18.0%$-6M$-6M-18.0%
Dec 2023$29M+2.2%$-10M$-14M-48.2%
Dec 2022$28M+18.8%$-11M$-9M-31.0%
Dec 2021$23M-2.9%$-7M$-5M-19.4%
Dec 2020$24M+4.4%$-1M$-1M-5.0%
Dec 2019$23M+33.5%$1M$1M2.4%
Dec 2018$17M—$1M$1M5.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$0M$1M$-0M$-0.06—
Dec 2024$-0M$1M$-2M$-0.13—
Dec 2023$-5M$1M$-6M$-0.30—
Dec 2022$-5M$3M$-8M$-0.19—
Dec 2021$-4M$0M$-5M$-0.10—
Dec 2020$-1M$1M$-2M$-0.03—
Dec 2019$0M$0M$0M$0.01—
Dec 2018$1M$0M$1M$0.02—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$46M
Net income, trailing 12 months
$-1M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $9M, net income $-2M$9MDec ’24Three months to Mar 2025: revenue $10M, net income $-1M$10MMar ’25Three months to Jun 2025: revenue $10M, net income $-0M$10MJun ’25Three months to Sep 2025: revenue $10M, net income $-1M$10MSep ’25Three months to Dec 2025 (from the annual report): revenue $11M, net income $-0M$11MDec ’25Three months to Mar 2026: revenue $12M, net income $-1M$12MMar ’26Three months to Jun 2026: revenue $12M, net income $0M$12MJun ’26Three months to Sep 2026: revenue $12M, net income $0M$12MSep ’26

Latest quarter to Sep 2026: revenue $12M (+11.2% on a year earlier), net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Repro Med Systems with the US Securities and Exchange Commission.

Annual results

Revenue
$41 M
Operating income
$-3 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$28 M
Total liabilities
$11 M
Total equity
$17 M

As of December-2025

Top 85 institutional investors in Repro Med Systems#

As of Sep 30, 2026
85 institutions held 20.2 M shares (about 46.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 35.7%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Repro Med Systems
#InstitutionShares heldChange (shares)% heldValueFiled
1Topline Capital Management, LLC4,333,201+959,359 (+28.44%)9.99%$13 MNov 16, 2026
2BlackRock, Inc.2,781,721+153,369 (+5.84%)6.41%$8 MNov 13, 2026
3First Light Asset Management, LLC2,745,372-642,530 (-18.97%)6.33%$8 MNov 16, 2026
4Vanguard Capital Management LLC1,690,732-127,389 (-7.01%)3.90%$5 MNov 13, 2026
5Geode Capital Management, LLC1,040,708-87,388 (-7.75%)2.40%$3 MNov 6, 2026
6Simcoe Capital LLC713,392-114,001 (-13.78%)1.64%$2 MNov 5, 2026
7Archon Capital Management LLC648,695+5,772 (+0.90%)1.50%$2 MNov 16, 2026
8State Street Corp634,332-12,240 (-1.89%)1.46%$2 MNov 12, 2026
9Meros Investment Management, LP508,779-250,885 (-33.03%)1.17%$1 MNov 17, 2026
10HRT Financial LP375,703+22,531 (+6.38%)0.87%$1 MNov 13, 2026
11Northern Trust Corp343,110-4,063 (-1.17%)0.79%$1 MNov 16, 2026
12Vanguard Portfolio Management LLC305,435-4,398 (-1.42%)0.70%$1 MNov 13, 2026
13White Pine Capital LLC286,644+2,541 (+0.89%)0.66%$1 MNov 9, 2026
14Vanguard Fiduciary Trust Co285,044-41,053 (-12.59%)0.66%$1 MNov 13, 2026
15Marshall Wace, LLP244,902+223,406 (+1039.29%)0.56%$1 MNov 13, 2026
16Renaissance Technologies LLC235,800+70,900 (+43.00%)0.54%$1 MNov 12, 2026
17Arrowstreet Capital, Limited Partnership213,782+160,910 (+304.34%)0.49%$1 MNov 13, 2026
18Morgan Stanley196,599-126,360 (-39.13%)0.45%$1 MNov 13, 2026
19Connor, Clark & Lunn Investment Management Ltd.188,397+35,453 (+23.18%)0.43%$1 MNov 10, 2026
20Albion Financial Group /ut186,3740 (0.00%)0.43%$1 MOct 21, 2026
21Squarepoint Ops LLC173,132+48,377 (+38.78%)0.40%$1 MNov 9, 2026
22Citadel Advisors LLC172,989+144,469 (+506.55%)0.40%$1 MNov 16, 2026
23Qube Research & Technologies Ltd137,527-62,412 (-31.22%)0.32%$0 MNov 13, 2026
24HighMark Wealth Management LLC120,9350 (0.00%)0.28%$0 MNov 17, 2026
25Goldman Sachs Group Inc120,375+19,900 (+19.81%)0.28%$0 MNov 16, 2026
Show all 85: investors 26 to 85
Institutional investors 26 to 85 in Repro Med Systems
#InstitutionShares heldChange (shares)% heldValueFiled
26Charles Schwab Investment Management Inc115,173-11,537 (-9.11%)0.27%$0 MNov 16, 2026
27Strs Ohio104,100+29,900 (+40.30%)0.24%$0 MOct 30, 2026
28PNC Financial Services Group, Inc.97,040+40 (+0.04%)0.22%$0 MNov 6, 2026
29Gsa Capital Partners LLP90,046+60,420 (+203.94%)0.21%$0 MNov 16, 2026
30Bank of New York Mellon Corp89,441+1,736 (+1.98%)0.21%$0 MNov 5, 2026
31Lakewood Asset Management LLC73,9450 (0.00%)0.17%$0 MOct 26, 2026
32Nuveen, LLC56,564+1,234 (+2.23%)0.13%$0 MNov 10, 2026
33HighTower Advisors, LLC51,400+25 (+0.05%)0.12%$0 MNov 10, 2026
34Bank Of America Corp /de/48,842+19,238 (+64.98%)0.11%$0 MNov 16, 2026
35Rhumbline Advisers44,899+15,768 (+54.13%)0.10%$0 MNov 10, 2026
36Acadian Asset Management LLC43,305New0.10%$0 MNov 9, 2026
37Deutsche Bank AG\38,160-5,445 (-12.49%)0.09%$0 MNov 6, 2026
38Price T Rowe Associates Inc /MD/36,9910 (0.00%)0.09%$0 MNov 16, 2026
39Bridgeway Capital Management, LLC36,805-15,000 (-28.95%)0.08%$0 MNov 16, 2026
40Invesco Ltd.36,689+1,353 (+3.83%)0.08%$0 MNov 12, 2026
41Osaic Holdings, Inc.32,570+8,300 (+34.20%)0.08%$0 MNov 12, 2026
42Quadrature Capital Ltd30,620New0.07%$0 MNov 13, 2026
43Corient Private Wealth LP29,885New0.07%$0 MNov 16, 2026
44Algert Global LLC28,107+5,370 (+23.62%)0.06%$0 MNov 17, 2026
45Two Sigma Investments, LP25,594+10,983 (+75.17%)0.06%$0 MNov 16, 2026
46Susquehanna International Group, LLP25,535New0.06%$0 MNov 16, 2026
47Dimensional Fund Advisors LP24,380New0.06%$0 MNov 4, 2026
48Russell Investments Group, Ltd.24,231-245,355 (-91.01%)0.06%$0 MNov 6, 2026
49Centiva Capital, LP24,215+9,003 (+59.18%)0.06%$0 MNov 13, 2026
50Wealthspire Advisors, LLC23,425+2,000 (+9.33%)0.05%$0 MNov 13, 2026
51Occudo Quantitative Strategies LP22,455-1,419 (-5.94%)0.05%$0 MNov 16, 2026
52Jpmorgan Chase & Co22,202+2,440 (+12.35%)0.05%$0 MNov 12, 2026
53MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.21,871+1,102 (+5.31%)0.05%$0 MNov 16, 2026
54Walleye Capital LLC21,364New0.05%$0 MNov 13, 2026
55Vanguard Global Advisers, LLC20,170+224 (+1.12%)0.05%$0 MNov 13, 2026
56Captrust Financial Advisors20,072New0.05%$0 MNov 12, 2026
57Barclays PLC16,754+10,191 (+155.28%)0.04%$0 MNov 6, 2026
58Mesirow Financial Investment Management, Inc.16,4590 (0.00%)0.04%$0 MNov 5, 2026
59Bard Associates Inc16,004+1,414 (+9.69%)0.04%$0 MNov 13, 2026
60Jump Financial, LLC14,015New0.03%$0 MNov 13, 2026
61Millennium Management LLC13,436-2,920 (-17.85%)0.03%$0 MNov 16, 2026
62Wells Fargo & Company/mn13,254-27,877 (-67.78%)0.03%$0 MNov 16, 2026
63New York State Common Retirement Fund13,1630 (0.00%)0.03%$0 MNov 17, 2026
64Engineers Gate Manager LP13,091New0.03%$0 MNov 16, 2026
65BNP Paribas Financial Markets11,546+3,724 (+47.61%)0.03%$0 MNov 12, 2026
66Baird Financial Group, Inc.11,000New0.03%$0 MNov 13, 2026
67UBS Group AG10,769+4,856 (+82.12%)0.02%$0 MNov 10, 2026
68Royal Bank Of Canada10,097+5,073 (+100.98%)0.02%$0 MNov 16, 2026
69Tower Research Capital LLC (TRC)9,431+5,861 (+164.17%)0.02%$0 MNov 16, 2026
70Police & Firemen's Retirement System of New Jersey8,2550 (0.00%)0.02%$0 MNov 9, 2026
71FMR LLC7,939+2,259 (+39.77%)0.02%$0 MNov 10, 2026
72Citigroup Inc5,781-15,357 (-72.65%)0.01%$0 MNov 4, 2026
73Ameritas Investment Partners, Inc.4,3360 (0.00%)0.01%$0 MNov 13, 2026
74Legal & General Group Plc3,8680 (0.00%)0.01%$0 MNov 16, 2026
75Steward Partners Investment Advisory, LLC1,898+1,078 (+131.46%)0.00%$0 MNov 13, 2026
76BFC Planning, Inc.1,5000 (0.00%)0.00%$0 MNov 13, 2026
77Sterling Capital Management LLC1,479+1,321 (+836.08%)0.00%$0 MOct 22, 2026
78California State Teachers Retirement System6060 (0.00%)0.00%$0 MNov 13, 2026
79TD Private Client Wealth LLC286New0.00%$0 MOct 28, 2026
80Allworth Financial LP56+36 (+180.00%)0.00%$0 MNov 17, 2026
81SJS Investment Consulting Inc.30+29 (+2900.00%)0.00%$0 MOct 26, 2026
82Nisa Investment Advisors, LLC250 (0.00%)0.00%$0 MOct 20, 2026
83Caitong International Asset Management Co., Ltd17+14 (+466.67%)0.00%$0 MOct 29, 2026
84Arax Advisory Partners2-17 (-89.47%)0.00%$0 MNov 12, 2026
85Essential Partners LLC1-2 (-66.67%)0.00%$0 MOct 14, 2026

Mutual funds holding Repro Med Systems#

61 funds hold shares worth $23 M (about 12.9% of the company). Since their previous reports 25 added shares and 12 sold, buying $1 M net.
Mutual funds holding Repro Med Systems
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.25 M$5 M2.9%<0.01%+13%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.14 M$5 M2.6%<0.01%+11%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.520,942$2 M1.2%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC488,221$2 M1.1%<0.01%+15%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors423,433$2 M0.98%0.01%+17%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC241,876$1 M0.56%<0.01%−0.7%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.222,972$1 M0.51%<0.01%+4.5%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors151,633$1 M0.35%0.04%+39%Jun 30, 2026
🇺🇸 SIMT Tax-Managed Small/Mid Cap FundSEI Institutional Managed Trust129,708$1 M0.30%0.07%−27%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.113,897$0 M0.26%<0.01%+20%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC83,808$0 M0.19%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC73,581$0 M0.17%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC70,974$0 M0.16%<0.01%+6.2%May 31, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.65,630$0 M0.15%0.03%+1.3%May 31, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC56,139$0 M0.13%0.20%—Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC55,330$0 M0.13%<0.01%no changeJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC42,991$0 M0.10%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC42,506$0 M0.10%0.01%+29%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.39,645$0 M0.09%<0.01%−0.9%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation30,800$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC31,356$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC24,670$0 M0.06%0.04%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.24,313$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.21,744$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC21,542$0 M0.05%<0.01%+13%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.18,124$0 M0.04%<0.01%−26%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.17,200$0 M0.04%<0.01%+29%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company16,177$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC15,406$0 M0.04%<0.01%+8.3%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.12,813$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC10,668$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,201$0 M0.02%0.02%+35%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC9,139$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS8,439$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC8,148$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC7,907$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC7,823$0 M0.02%0.02%−2.9%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC7,332$0 M0.02%<0.01%+36%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,134$0 M0.02%<0.01%+32%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.6,797$0 M0.02%<0.01%+41%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.6,492$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC5,165$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,977$0 M0.01%<0.01%+0.4%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC4,828$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,336$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC4,277$0 M<0.01%0.01%+33%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC4,145$0 M<0.01%<0.01%+36%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION4,100$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,650$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,518$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,448$0 M<0.01%<0.01%+6.3%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,237$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,100$0 M<0.01%<0.01%+72%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC3,100$0 M<0.01%<0.01%+72%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,033$0 M<0.01%<0.01%+8.5%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,590$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,608$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,413$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,398$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,026$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.244$0 M<0.01%<0.01%+16%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 61 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Repro Med Systems#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$242 K
9 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$242 K
open market only
Insiders on file
34
since
$350 K-$350 K$0Dec 2023: bought $350 K (1 trades), sold $350 K (1 trades)Dec 23May 2026: bought $60 K (5 trades), sold $0 (0 trades)MayJun 2026: bought $49 K (2 trades), sold $0 (0 trades)JunSep 2026: bought $101 K (1 trades), sold $0 (0 trades)SepNov 2026: bought $31 K (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Repro Med Systems: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Eric SchillerChief Technology OfficerBuy+8,546$3.630$31 K13,546Form 4
filed Robert CascellaDirectorGrant or award+5,119$2.930$15 K103,274Form 4
filed R. John FletcherDirectorGrant or award+7,679$2.930$22 K239,836Form 4
filed Donna FrenchDirectorGrant or award+5,119$2.930$15 K103,633Form 4
filed Shahriar MatinDirectorGrant or award+5,119$2.930$15 K106,263Form 4
filed Edward WholihanDirectorGrant or award+5,119$2.930$15 K56,431Form 4
filed Joseph M. Manko Jr.Director, 10% ownerGrant or awardindirect+5,119——5.07 MForm 4
filed Adam R. KalbermattenChief Commercial OfficerBuy+32,000$3.160$101 K394,017Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Repro Med Systems#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
861,413
1.9% of shares · 6.55 days to cover
Buybacks, Q4 2019
$0M
Q4 2020
Shares sold short, last 24 reportsAll stocks →
Repro Med Systems share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2019Q4 2020$0M
Q3 2019Q3 2020$0M
Q2 2019Q2 2020$0M
Q1 2019Q1 2020$0M

Fails to deliver

  • : 5,015 shares at $3.22
  • : 1,024 shares at $3.02
  • : 10,595 shares at $3.00
  • : 94,311 shares at $3.22
  • : 96,411 shares at $3.20

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Repro Med Systems scorecard#

Passes 8 of the 20 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median8.2×Price to book 8.2× against Medical Instruments's median of 3.9×.
    • ✗Price to sales below its peers' median3.0×Price to sales 3.0× against Medical Instruments's median of 3.0×.
    • ✗Free cash flow yield above 5%-0.3%Free cash flow is -0.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year22.2%Revenue up 22.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years13.8%13.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median13.8%13.8% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✗Earnings per share grew in the newest year-0.06 vs -0.13Diluted EPS -0.06 in fiscal 2025 against -0.13 the year before (report's currency).
    • ✗Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$1 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-7.2%-7.2% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%-15.6%-15.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-7.2%-7.2% in fiscal 2025 against -38.6% in 2022.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.44 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone7.54Z-score 7.54 (safe zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.8%Diluted shares up 0.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Repro Med Systems's statements, beside the median of Medical Instruments.

Repro Med Systems: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-7.2%7.2%
Net margin-6.4%3.8%
Return on equity-15.6%3.5%
Revenue growth, 3 years a year13.8%5.0%
Revenue growth22.2%8.9%
Free cash flow margin-1.1%6.3%

4of 8on the Piotroski tests of financial strength

  • Net loss of $3 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$0 million.
  • Revenue has grown 4 years in a row.

Repro Med Systems: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Repro Med Systems: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2016to Feb 28, 2017FY 2015to Feb 29, 2016
Income statement
Revenue41,12733,64628,51827,89623,49024,17623,16317,35412,29412,247
Cost of revenue15,52312,31511,80912,5279,7219,2408,3096,5434,7244,644
Gross profit25,60421,33216,70815,36913,77014,93614,85410,8107,5707,603
Research and development4,3875,2585,7424,9562,4741,297740241237207
Selling, general and administrative23,37921,63220,36620,60717,86212,0289,7728,197r7,7685,943
Operating expenses28,57727,77826,97826,15020,79916,19114,2689,6468,3066,422
Operating income−2,972−6,446−10,270−10,781−7,030−1,2555861,165−7361,181
Interest expense and finance costs————————1.93.4
Provision for credit losses—————−8.2−4.9−40——
Other non-operating income (expense)35638249610666561111r282.9−9.2
Income before tax−2,616−6,064−9,774−10,675−6,364r1,194r6961,177−7771,143
Income tax222.93,967−2,014−1,802r−18r132266−242360
Net income attributable to shareholders−2,638−6,067−13,741−8,661−4,563−1,212564911−535783
Earnings per share, basic-0.06-0.13-0.30-0.19-0.10-0.030.010.02-0.010.02
Earnings per share, diluted-0.06-0.13-0.30-0.19-0.10-0.030.010.02-0.010.02
Shares, weighted average (basic)46464645444239383838
Shares, weighted average (diluted)46464645444239393838
Balance sheet
Cash and cash equivalents8,8729,58111,48217,40825,33527,3155,8713,7393,3134,202r
Receivables6,2105,7214,0453,5593,5932,5733,2351,4261,5021,350
Inventory3,6782,8043,4816,4056,1066,8302,3882,1041,3541,040
Current assets19,98919,13220,25629,80237,32137,52611,8819,0336,7807,119
Property, plant and equipment4,4714,2913,8383,8871,1061,168612859932997
Right-of-use (leased) assets2,9562,9663,5143,78796237374———
Other intangible assets685730754787809844807632427248
Total assets28,20027,21928,46142,33241,29339,91913,88210,5458,1708,394
Accounts payable2,2671,6509752,3921,228625573453772308
Current liabilities8,1947,2024,4546,9594,7923,6662,4061,5841,3891,108
Lease liabilities (non-current)2,8793,0003,3363,653—96237———
Total liabilities11,15210,4058,10711,0064,7923,7622,6461,5841,4941,276
Retained earnings−32,017−29,379−23,312−9,571−9103,6534,8654,3002,4853,020
Shareholders' equity17,04816,81420,35431,32636,50136,15711,2368,9616,6767,118
Total liabilities and equity28,20027,21928,46142,33241,29339,91913,88210,5458,1708,394
Shares outstanding464646r45454340383838
Cash-flow statement
Depreciation and amortization811888870587463419340309301272
Share-based compensation2,7142,6242,7693,0792,7081,6191,205366205115
Cash from operating activities462−320−4,893−5,405−4,320−7433211,480−3321,915
Capital expenditure−933−1,297−783−2,761−346−921−201−297−203−122
Intangible assets bought−24−44−32−41−29−141−224−184−212−80
Cash from investing activities−950−1,333−815−2,802−366−1,0361,310−1,730−416−190
Shares issued———4071,26126,72850951——
Shares bought back——————−2.8———
Cash from financing activities−221−249−2192792,70523,22450114−141−81
Change in cash−709−1,901−5,926−7,927−1,98021,4442,132−236−8891,645
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Repro Med Systems sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Repro Med Systems#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.7 M
Linda Tharby
Other top executives, average
$1.8 M
the CEO earned 1× this
$100 invested is now
$163
Repro Med Systems: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Linda Tharby$1.7 M$3.2 M$1.8 M$163
2024Linda Tharby$1.3 M$1.9 M$599 K$108
2023Linda Tharby$713 K−$1.2 M$547 K$69

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Repro Med Systems#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 4 · Material agreement 5 · New debt 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 13

Repro Med Systems: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Material agreementNew debt8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Auditor changed8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Lobbying by Repro Med Systems#

$0 spent on lobbying the US Congress and federal agencies in 2018.

Lobbying, 2018
$0
#1,156 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2018
2026 so far
—

Lobbying firms hired in 2018

Dan Burton International LLC

Repro Med Systems: lobbying spending by year
YearSpendingOwn lobbyistsReports
2018$0—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Repro-Med Systems, Inc., d/b/a RMS Medical Products”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Product recalls by Repro Med Systems#

2 recalls since 2015, 1,990 units in the notices that give a number. Medical devices (FDA): 2.

Repro Med Systems: product recalls
DateWhat and whyUnitsNotice
20" 2-Needle 26-Gauge 6mm HlgH-Flo Subcutaneous Safety Needle Sets" Product # RMS22606 - Product Usage: RMS HlgH-Flo Subcutaneous Safety Needle Sets are intended for the delivery of medication to the subcutaneous tissue.Mislabeled needle lengthsMedical devicesClass II1,990Z-0051-2020
Freedom60 Precision Flow Rate Tubing Sets, REF/Part Numbers F900, F2400, F60, F10, F275, F600, F45, F1200 F180. (and 1 more products)On 2/24/2016 during post sterilization inspection of part number F180 Precision Flow Rate Tubing, Lot number 1.042/16 the firm found 701 out of 3,195 were rejected due to visual defect, gap in the supplier s manufacturing seal for Part number #317036 5 X 6.5 ST Bag Combo. the firm decided to recall Precision Flow Rate Tubing and RMS HIgH-Flo Subcutaneous Safety Needles Sets due to the sterile barrier packaging being found to have gaps during post-sterilization inspection of one lot of flow tubing, in which 701 out of 3,195 units were rejected for not passing inspection. The firm determined that the issue was large than just the one lot and recalled the product via March 10, 2016 Voluntary Medical Device Corrections and Removal Notification to customers. The recall was conducted without FDA notification.Medical devicesClass II—Z-0317-2018

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

How Repro Med Systems compares in Medical Instruments

  • Market cap$140 M · higher than 20% of 116
  • Revenue$41 M · higher than 14% of 120
  • Net margin-1.8% · higher than 21% of 114
  • Revenue growth22.2% · higher than 88% of 49
  • Price / sales3.0× · lower than 51% of 85
  • Price / book8.2× · lower than 12% of 84
  • FCF yield-0.3% · higher than 34% of 39

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Repro Med Systems🇺🇸$140 M—-1.8%+22.2%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Repro Med Systems? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Repro Med Systems's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Repro Med Systems? Suggest a correction